Merck Signs a Five-Year Agreement with M2GEN to Advance Cancer Therapies
Shots:
- The companies collaborated to accelerate the discovery and development of novel therapies for patients with cancer indications.M2GEN will provide valuable patient-consented- de-identified clinical and genomic data to support Merck's oncology efforts
- The data will be accessed through M2GEN's ORIEN which is a network of 18 cancer centers across the US
- The collaboration provides utility in Merck's oncology development programs including indications for Keytruda (pembrolizumab)
Ref: PRNewswire | Image: Merck
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com